{"id":"NCT02263326","sponsor":"Babafemi Taiwo","briefTitle":"Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure","officialTitle":"Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12","primaryCompletion":"2017-07","completion":"2017-09","firstPosted":"2014-10-13","resultsPosted":"2018-11-13","lastUpdate":"2019-10-14"},"enrollment":89,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infection"],"interventions":[{"type":"DRUG","name":"dolutegravir","otherNames":["TIVICAY, DTG"]},{"type":"DRUG","name":"lamivudine","otherNames":["EPIVIR, 3TC"]},{"type":"DRUG","name":"Continue current antiretroviral regimen","otherNames":[]}],"arms":[{"label":"dolutegravir plus lamivudine","type":"EXPERIMENTAL"},{"label":"Continue current ART regimen","type":"ACTIVE_COMPARATOR"}],"summary":"HIV-1 infected subjects with CD4 nadir \\> 200 cells/mm3, no history of virologic failure and plasma HIV RNA \\<50 copies/mL for at least 48 weeks while on any United States Department of Health and Human Services (DHHS) recommended or alternative three-drug antiretroviral regimen will be randomized to dolutegravir (DTG) plus lamivudine (Arm 1) or continuation of their current regimen (Arm 2) for 48 weeks. The primary endpoint is virologic failure defined as confirmed plasma HIV-1 RNA \\> 50 copies/mL before or at Week 24","primaryOutcome":{"measure":"Proportion of Participants With Treatment Failure","timeFrame":"24 weeks","effectByArm":[{"arm":"Dolutegravir Plus Lamivudine","deltaMin":0.0682,"sd":null},{"arm":"Continue Current ART Regimen","deltaMin":0.0667,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":8},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":["29293895"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":44},"commonTop":["Grade 3 bilirubinemia"]}}